F045 - Field Cancer and Multiple SCC: Molecular Insights and Clinical Management
Saturday, March 2; 9:00 AM - 11:00 AM
Following this course, the attendee should be able to:
- Identify patients at risk for multiple SCC development.
- Recognize the progression from ultraviolet injury to actinic keratosis to SCC development within a field of actinic damage.
- Select and prescribe appropriate topical, systemic, or procedural field treatment for patients with multiple lesions.
Development of multiple SCCs within areas of actinic damage is common and is best described by the field cancerization paradigm. This session, designed for general dermatologists and dermatologic surgeons, will discuss the concept of precursor lesions and how ultraviolet-induced genetic mutations promote SCC development in sun-damaged skin. We now have clear evidence that prevention and field therapy can prevent SCCs. The use of topical, procedural, and systemic field therapy in appropriate patients will be reviewed. Participants will learn how to select the optimal strategy for individual patients, including combination treatment and management of high-risk populations such as organ transplant recipients.
- Ceilley, Roger I., MD: Aclaris Therapeutics Inc. – A(H); Biofrontera AG – A(H); Ferndale Laboratories, Inc. – A(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – A(H);
- Christensen, Sean, MD, PhD: Novartis – I(Grants/Research Funding); PellePharm, Inc. – I(Grants/Research Funding);
- Colegio, Oscar, MD, PhD: no financial relationships exist with commercial interests.
- Weinstock, Martin A., MD, PhD: AbbVie – C(Fees); Department. of Veterans Affairs – E(S);
Saturday, March 2
Dr. Christensen / Intro to Field Cancer and Topical Therapy
Dr. Weinstock / Natural History of AK and Chemoprevention of SCC
Dr. Ceilley / Photodynamic Field Therapy
Dr. Colegio / Field Therapy in Organ Transplant Recipients
Dr. Christensen / Surgical/Combination Treatment and Summary